My name is Marina Botto.
I'm a Professor of Rheumatology at the Imperial College,
and I'm interested in the role of the complement in systemic lupus erythematosus.
In these slides, I'm just summarize some of
the key points that I would like to cover today.
First, I will start with a discussion of the value of measuring complement in lupus,
and discuss whether these measurement are clinically helpful.
Then I will briefly discuss the paradoxical role of complement in lupus pathogenesis,
and highlighting the different role of the C1q and C3.
And we'll also mention recent study linking lupus to
some genetic polymorphisms in the complement system to
demonstrate how complement biology is not just an old story.
I would like also to mention the role of
anti-C1q antibodies in the context of this disease.
Finally, I will close by mentioning the potential role
that complement therapy may have in this disease in the future.
Lupus is systemic autoimmune disease that affects mainly women,
and there is a female-male ratio of nine to one.
It's a disease that has higher prevalence in a certain ethnic groups and particularly,
African-Caribbean and Hispanic population.
It's a disease as it's chronic,
but is characterized by a clinical course with the flare and remissions.
And the key feature of the disease is the breakdown in immune tolerance.
It's usually abbreviated as SLE.